Pfizer Launches $3.5 Billion Cost-Cutting Program Amid Declining Covid Vaccine Sales
Pfizer is implementing a “cost realignment program” expected to save the pharmaceutical giant at least $3.5 billion as it prepares for revenue drops for its Covid-19 vaccine and Paxlovid, a prescription pill for treating Covid-19, according to its updated full-year guidance. Pfizer expects the…
#pfizer #cdc #covidvaccine
